Recent Updates
Recently added Catalysts

LE

Phase 1

Pharmacokinetics | Small molecule | Other |Bausch + Lomb Corporation|Last Updated: Nov 8, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment12
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01736527Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single InstillationPHASE1 COMPLETED 12Jan 1, 2013Apr 1, 2013Nov 8, 20131 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Tear Fluid Levels
6 hours

Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
Treatment Arms
ArmTypeDescription
LE GelEXPERIMENTALA single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
Interventions
NameTypeDescription
LE GelDRUGSingle drop of LE Gel 0.5% administered to the study eye on visit 2
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Subjects must be healthy volunteers with physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. * Subjects must have a best-corrected visual acuity of 20/20 or better in each eye. * Subjects must have no active ocular disease or ...

Countries:United States
Unlock Eligibility Criteria